From COVID Moonshot to Pipeline Pivot — Pfizer's 2026 Strategy

Pfizer is in the middle of one of the most consequential strategic pivots in big pharma — moving from the COVID-era windfall into a high-stakes race to replace patent-cliff revenue with a new generation of drugs in oncology, obesity, and rare disease. This module gives candidates the strategic context they need to talk credibly about Pfizer's direction and answer "Why now?" questions with substance.